Report cover image

Global Alpha L-Iduronidase Market Outlook and Growth Opportunities 2025

Publisher APO Research, Inc.
Published Aug 16, 2025
Length 192 Pages
SKU # APRC20360700

Description

Summary

According to APO Research, the global Alpha L-Iduronidase market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.

The North American market for Alpha L-Iduronidase is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Asia-Pacific market for Alpha L-Iduronidase is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

In China, the Alpha L-Iduronidase market is expected to rise from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The Europe market for Alpha L-Iduronidase is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Major global companies in the Alpha L-Iduronidase market include ArmaGen Inc, BioStrategies LC, Denali Therapeutics Inc, EdiGene Inc, Gain Therapeutics Inc, Immusoft Corp, JCR Pharmaceuticals Co Ltd, Orchard Therapeutics Plc and Ossianix Inc, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Alpha L-Iduronidase, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Alpha L-Iduronidase, also provides the sales of main regions and countries. Of the upcoming market potential for Alpha L-Iduronidase, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Alpha L-Iduronidase sales, revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Alpha L-Iduronidase market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2020 to 2031. Evaluation and forecast the market size for Alpha L-Iduronidase sales, projected growth trends, production technology, application and end-user industry.

Alpha L-Iduronidase Segment by Company

ArmaGen Inc
BioStrategies LC
Denali Therapeutics Inc
EdiGene Inc
Gain Therapeutics Inc
Immusoft Corp
JCR Pharmaceuticals Co Ltd
Orchard Therapeutics Plc
Ossianix Inc
Rain Bio Inc
RegenxBio Inc
Tega Therapeutics Inc
Alpha L-Iduronidase Segment by Type

IDUA
EC 3.2.1.76
Alpha L-Iduronidase Segment by Application

Oncology
Dermatology
Immunology
Musculoskeletal Disorders
Alpha L-Iduronidase Segment by Region

North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global Alpha L-Iduronidase status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions Alpha L-Iduronidase market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Alpha L-Iduronidase significant trends, drivers, influence factors in global and regions.
6. To analyze Alpha L-Iduronidase competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Alpha L-Iduronidase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Alpha L-Iduronidase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Alpha L-Iduronidase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Alpha L-Iduronidase market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2020-2031).
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Alpha L-Iduronidase industry.
Chapter 3: Detailed analysis of Alpha L-Iduronidase manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales and value of Alpha L-Iduronidase in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 7: Sales and value of Alpha L-Iduronidase in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights.

Table of Contents

192 Pages
1 Market Overview
1.1 Product Definition
1.2 Global Market Growth Prospects
1.2.1 Global Alpha L-Iduronidase Sales Value (2020-2031)
1.2.2 Global Alpha L-Iduronidase Sales Volume (2020-2031)
1.2.3 Global Alpha L-Iduronidase Sales Average Price (2020-2031)
1.3 Assumptions and Limitations
1.4 Study Goals and Objectives
2 Alpha L-Iduronidase Market Dynamics
2.1 Alpha L-Iduronidase Industry Trends
2.2 Alpha L-Iduronidase Industry Drivers
2.3 Alpha L-Iduronidase Industry Opportunities and Challenges
2.4 Alpha L-Iduronidase Industry Restraints
3 Alpha L-Iduronidase Market by Company
3.1 Global Alpha L-Iduronidase Company Revenue Ranking in 2024
3.2 Global Alpha L-Iduronidase Revenue by Company (2020-2025)
3.3 Global Alpha L-Iduronidase Sales Volume by Company (2020-2025)
3.4 Global Alpha L-Iduronidase Average Price by Company (2020-2025)
3.5 Global Alpha L-Iduronidase Company Ranking (2023-2025)
3.6 Global Alpha L-Iduronidase Company Manufacturing Base and Headquarters
3.7 Global Alpha L-Iduronidase Company Product Type and Application
3.8 Global Alpha L-Iduronidase Company Establishment Date
3.9 Market Competitive Analysis
3.9.1 Global Alpha L-Iduronidase Market Concentration Ratio (CR5 and HHI)
3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
3.9.3 2024 Alpha L-Iduronidase Tier 1, Tier 2, and Tier 3 Companies
3.10 Mergers and Acquisitions Expansion
4 Alpha L-Iduronidase Market by Type
4.1 Alpha L-Iduronidase Type Introduction
4.1.1 IDUA
4.1.2 EC 3.2.1.76
4.2 Global Alpha L-Iduronidase Sales Volume by Type
4.2.1 Global Alpha L-Iduronidase Sales Volume by Type (2020 VS 2024 VS 2031)
4.2.2 Global Alpha L-Iduronidase Sales Volume by Type (2020-2031)
4.2.3 Global Alpha L-Iduronidase Sales Volume Share by Type (2020-2031)
4.3 Global Alpha L-Iduronidase Sales Value by Type
4.3.1 Global Alpha L-Iduronidase Sales Value by Type (2020 VS 2024 VS 2031)
4.3.2 Global Alpha L-Iduronidase Sales Value by Type (2020-2031)
4.3.3 Global Alpha L-Iduronidase Sales Value Share by Type (2020-2031)
5 Alpha L-Iduronidase Market by Application
5.1 Alpha L-Iduronidase Application Introduction
5.1.1 Oncology
5.1.2 Dermatology
5.1.3 Immunology
5.1.4 Musculoskeletal Disorders
5.2 Global Alpha L-Iduronidase Sales Volume by Application
5.2.1 Global Alpha L-Iduronidase Sales Volume by Application (2020 VS 2024 VS 2031)
5.2.2 Global Alpha L-Iduronidase Sales Volume by Application (2020-2031)
5.2.3 Global Alpha L-Iduronidase Sales Volume Share by Application (2020-2031)
5.3 Global Alpha L-Iduronidase Sales Value by Application
5.3.1 Global Alpha L-Iduronidase Sales Value by Application (2020 VS 2024 VS 2031)
5.3.2 Global Alpha L-Iduronidase Sales Value by Application (2020-2031)
5.3.3 Global Alpha L-Iduronidase Sales Value Share by Application (2020-2031)
6 Alpha L-Iduronidase Regional Sales and Value Analysis
6.1 Global Alpha L-Iduronidase Sales by Region: 2020 VS 2024 VS 2031
6.2 Global Alpha L-Iduronidase Sales by Region (2020-2031)
6.2.1 Global Alpha L-Iduronidase Sales by Region: 2020-2025
6.2.2 Global Alpha L-Iduronidase Sales by Region (2026-2031)
6.3 Global Alpha L-Iduronidase Sales Value by Region: 2020 VS 2024 VS 2031
6.4 Global Alpha L-Iduronidase Sales Value by Region (2020-2031)
6.4.1 Global Alpha L-Iduronidase Sales Value by Region: 2020-2025
6.4.2 Global Alpha L-Iduronidase Sales Value by Region (2026-2031)
6.5 Global Alpha L-Iduronidase Market Price Analysis by Region (2020-2025)
6.6 North America
6.6.1 North America Alpha L-Iduronidase Sales Value (2020-2031)
6.6.2 North America Alpha L-Iduronidase Sales Value Share by Country, 2024 VS 2031
6.7 Europe
6.7.1 Europe Alpha L-Iduronidase Sales Value (2020-2031)
6.7.2 Europe Alpha L-Iduronidase Sales Value Share by Country, 2024 VS 2031
6.8 Asia-Pacific
6.8.1 Asia-Pacific Alpha L-Iduronidase Sales Value (2020-2031)
6.8.2 Asia-Pacific Alpha L-Iduronidase Sales Value Share by Country, 2024 VS 2031
6.9 South America
6.9.1 South America Alpha L-Iduronidase Sales Value (2020-2031)
6.9.2 South America Alpha L-Iduronidase Sales Value Share by Country, 2024 VS 2031
6.10 Middle East & Africa
6.10.1 Middle East & Africa Alpha L-Iduronidase Sales Value (2020-2031)
6.10.2 Middle East & Africa Alpha L-Iduronidase Sales Value Share by Country, 2024 VS 2031
7 Alpha L-Iduronidase Country-level Sales and Value Analysis
7.1 Global Alpha L-Iduronidase Sales by Country: 2020 VS 2024 VS 2031
7.2 Global Alpha L-Iduronidase Sales Value by Country: 2020 VS 2024 VS 2031
7.3 Global Alpha L-Iduronidase Sales by Country (2020-2031)
7.3.1 Global Alpha L-Iduronidase Sales by Country (2020-2025)
7.3.2 Global Alpha L-Iduronidase Sales by Country (2026-2031)
7.4 Global Alpha L-Iduronidase Sales Value by Country (2020-2031)
7.4.1 Global Alpha L-Iduronidase Sales Value by Country (2020-2025)
7.4.2 Global Alpha L-Iduronidase Sales Value by Country (2026-2031)
7.5 USA
7.5.1 USA Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.5.2 USA Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.5.3 USA Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.6 Canada
7.6.1 Canada Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.6.2 Canada Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.6.3 Canada Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.7 Mexico
7.6.1 Mexico Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.6.2 Mexico Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.6.3 Mexico Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.8 Germany
7.8.1 Germany Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.8.2 Germany Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.8.3 Germany Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.9 France
7.9.1 France Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.9.2 France Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.9.3 France Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.10 U.K.
7.10.1 U.K. Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.10.2 U.K. Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.10.3 U.K. Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.11 Italy
7.11.1 Italy Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.11.2 Italy Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.11.3 Italy Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.12 Spain
7.12.1 Spain Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.12.2 Spain Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.12.3 Spain Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.13 Russia
7.13.1 Russia Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.13.2 Russia Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.13.3 Russia Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.14 Netherlands
7.14.1 Netherlands Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.14.2 Netherlands Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.14.3 Netherlands Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.15 Nordic Countries
7.15.1 Nordic Countries Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.15.2 Nordic Countries Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.15.3 Nordic Countries Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.16 China
7.16.1 China Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.16.2 China Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.16.3 China Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.17 Japan
7.17.1 Japan Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.17.2 Japan Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.17.3 Japan Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.18 South Korea
7.18.1 South Korea Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.18.2 South Korea Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.18.3 South Korea Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.19 India
7.19.1 India Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.19.2 India Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.19.3 India Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.20 Australia
7.20.1 Australia Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.20.2 Australia Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.20.3 Australia Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.21 Southeast Asia
7.21.1 Southeast Asia Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.21.2 Southeast Asia Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.21.3 Southeast Asia Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.22 Brazil
7.22.1 Brazil Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.22.2 Brazil Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.22.3 Brazil Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.23 Argentina
7.23.1 Argentina Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.23.2 Argentina Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.23.3 Argentina Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.24 Chile
7.24.1 Chile Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.24.2 Chile Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.24.3 Chile Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.25 Colombia
7.25.1 Colombia Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.25.2 Colombia Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.25.3 Colombia Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.26 Peru
7.26.1 Peru Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.26.2 Peru Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.26.3 Peru Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.27 Saudi Arabia
7.27.1 Saudi Arabia Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.27.2 Saudi Arabia Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.27.3 Saudi Arabia Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.28 Israel
7.28.1 Israel Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.28.2 Israel Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.28.3 Israel Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.29 UAE
7.29.1 UAE Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.29.2 UAE Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.29.3 UAE Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.30 Turkey
7.30.1 Turkey Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.30.2 Turkey Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.30.3 Turkey Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.31 Iran
7.31.1 Iran Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.31.2 Iran Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.31.3 Iran Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
7.32 Egypt
7.32.1 Egypt Alpha L-Iduronidase Sales Value Growth Rate (2020-2031)
7.32.2 Egypt Alpha L-Iduronidase Sales Value Share by Type, 2024 VS 2031
7.32.3 Egypt Alpha L-Iduronidase Sales Value Share by Application, 2024 VS 2031
8 Company Profiles
8.1 ArmaGen Inc
8.1.1 ArmaGen Inc Comapny Information
8.1.2 ArmaGen Inc Business Overview
8.1.3 ArmaGen Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.1.4 ArmaGen Inc Alpha L-Iduronidase Product Portfolio
8.1.5 ArmaGen Inc Recent Developments
8.2 BioStrategies LC
8.2.1 BioStrategies LC Comapny Information
8.2.2 BioStrategies LC Business Overview
8.2.3 BioStrategies LC Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.2.4 BioStrategies LC Alpha L-Iduronidase Product Portfolio
8.2.5 BioStrategies LC Recent Developments
8.3 Denali Therapeutics Inc
8.3.1 Denali Therapeutics Inc Comapny Information
8.3.2 Denali Therapeutics Inc Business Overview
8.3.3 Denali Therapeutics Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.3.4 Denali Therapeutics Inc Alpha L-Iduronidase Product Portfolio
8.3.5 Denali Therapeutics Inc Recent Developments
8.4 EdiGene Inc
8.4.1 EdiGene Inc Comapny Information
8.4.2 EdiGene Inc Business Overview
8.4.3 EdiGene Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.4.4 EdiGene Inc Alpha L-Iduronidase Product Portfolio
8.4.5 EdiGene Inc Recent Developments
8.5 Gain Therapeutics Inc
8.5.1 Gain Therapeutics Inc Comapny Information
8.5.2 Gain Therapeutics Inc Business Overview
8.5.3 Gain Therapeutics Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.5.4 Gain Therapeutics Inc Alpha L-Iduronidase Product Portfolio
8.5.5 Gain Therapeutics Inc Recent Developments
8.6 Immusoft Corp
8.6.1 Immusoft Corp Comapny Information
8.6.2 Immusoft Corp Business Overview
8.6.3 Immusoft Corp Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.6.4 Immusoft Corp Alpha L-Iduronidase Product Portfolio
8.6.5 Immusoft Corp Recent Developments
8.7 JCR Pharmaceuticals Co Ltd
8.7.1 JCR Pharmaceuticals Co Ltd Comapny Information
8.7.2 JCR Pharmaceuticals Co Ltd Business Overview
8.7.3 JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.7.4 JCR Pharmaceuticals Co Ltd Alpha L-Iduronidase Product Portfolio
8.7.5 JCR Pharmaceuticals Co Ltd Recent Developments
8.8 Orchard Therapeutics Plc
8.8.1 Orchard Therapeutics Plc Comapny Information
8.8.2 Orchard Therapeutics Plc Business Overview
8.8.3 Orchard Therapeutics Plc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.8.4 Orchard Therapeutics Plc Alpha L-Iduronidase Product Portfolio
8.8.5 Orchard Therapeutics Plc Recent Developments
8.9 Ossianix Inc
8.9.1 Ossianix Inc Comapny Information
8.9.2 Ossianix Inc Business Overview
8.9.3 Ossianix Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.9.4 Ossianix Inc Alpha L-Iduronidase Product Portfolio
8.9.5 Ossianix Inc Recent Developments
8.10 Rain Bio Inc
8.10.1 Rain Bio Inc Comapny Information
8.10.2 Rain Bio Inc Business Overview
8.10.3 Rain Bio Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.10.4 Rain Bio Inc Alpha L-Iduronidase Product Portfolio
8.10.5 Rain Bio Inc Recent Developments
8.11 RegenxBio Inc
8.11.1 RegenxBio Inc Comapny Information
8.11.2 RegenxBio Inc Business Overview
8.11.3 RegenxBio Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.11.4 RegenxBio Inc Alpha L-Iduronidase Product Portfolio
8.11.5 RegenxBio Inc Recent Developments
8.12 Tega Therapeutics Inc
8.12.1 Tega Therapeutics Inc Comapny Information
8.12.2 Tega Therapeutics Inc Business Overview
8.12.3 Tega Therapeutics Inc Alpha L-Iduronidase Sales, Value and Gross Margin (2020-2025)
8.12.4 Tega Therapeutics Inc Alpha L-Iduronidase Product Portfolio
8.12.5 Tega Therapeutics Inc Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Alpha L-Iduronidase Value Chain Analysis
9.1.1 Alpha L-Iduronidase Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Alpha L-Iduronidase Sales Mode & Process
9.2 Alpha L-Iduronidase Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Alpha L-Iduronidase Distributors
9.2.3 Alpha L-Iduronidase Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
How Do Licenses Work?
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.